Mironid® Limited
United Kingdom
- North Lanarkshire
- 14/09/2023
- Series A
- Undisclosed Amount
Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.
- Industry Pharmaceutical Manufacturing
- Website https://www.mironid.com/
- LinkedIn https://www.linkedin.com/company/mironid-limited/
Related People
Neil WilkieFounder
United Kingdom -
Greater Glasgow Area
Experienced C-level Pharmaceutical Executive with extensive experience of technical drug discovery combined with investment and company building experience. Graduate of MIT's Global Entrepreneurship Development Program.
Dynamic and versatile with 25+ years’ experience of delivering value from investments in the pharmaceutical and biotechnology sectors. A high-energy enthusiastic leader with a strong strategic aptitude and relationship-building style who leads with the end-goal in mind, utilising established senior-level networks, a proven history of leadership and a track record of channeling strategic vision into defined plans of action.
Specialties: Pharmaceutical Drug Development, Company Creation & Building, Business and Investment Analysis, Corporate Programme Management.
WealthAi | $1,000,000 | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)
PaleBlueDot AI | $150,000,000 | (Jan 30, 2026)
Mesh Security | $12,000,000 | (Jan 30, 2026)
Datalinx AI | $4,200,000 | (Jan 30, 2026)
Ressio Software | Undisclosed Amount | (Jan 30, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)
Arkero | $6,000,000 | (Jan 30, 2026)
Redwood Materials | $425,000,000 | (Jan 30, 2026)
Twogee Biotech | $2,575,886 | (Jan 30, 2026)
Levellr | $2,500,000 | (Jan 30, 2026)
Indigo(1) | $50,000,000 | (Jan 30, 2026)
heyData | $16,500,000 | (Jan 30, 2026)